Linked Life Data

15675483

Source:http://linkedlifedata.com/resource/pubmed/id/15675483

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-1-28
pubmed:abstractText
Liposome-containing doxorubicin has been employed in the treatment of advanced soft tissue limb sarcoma during hyperthermic perfusion. A phase I-II study was carried out starting with a standard dose of 10 mg//L of limb volume, the dosage was escalated with 2 mg for each triplet of patients. The maximum tolerable (MTD) dose was established as the amount able to cause a grade IV limb reaction at least in two out of three patients, the temperature level remained unchanged (41.5 degrees C). The grade of limb reaction ranged between I-II (mild edema and erythema). Only in two patients treated with 18 mg/L of limb volume was a grade IV limb reaction observed, therefore MTD at a temperature of 41.5 degrees C is 16 mg. A good tumor response was observed in 29% of the patients, partial response in 71%. The tumor shrinkage after perfusion permitted conservative surgery in 91% of the cases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1120-009X
pubmed:author
pubmed:issnType
Print
pubmed:volume
16 Suppl 5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
66-9
pubmed:dateRevised
2009-8-4
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma.
pubmed:affiliation
Regina Elena National Cancer Institute - Rome, Italy. difilippo@ifo.it
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I